Status:
COMPLETED
Pharmacogenetics of Cannabinoid Response
Lead Sponsor:
Yale University
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
Conditions:
COMT Gene Polymorphism
Eligibility:
All Genders
18-55 years
Phase:
EARLY_PHASE1
Brief Summary
This study attempts to examine genetic influences on the effects of tetrahydrocannabinol (Δ9-THC), the active ingredient of marijuana, cannabis, "ganja", or "pot".
Eligibility Criteria
Inclusion
- 18 and 55 years (extremes included) on the day of the first dosing.
Exclusion
- Cannabis naïve individuals.
Key Trial Info
Start Date :
August 23 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 11 2014
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT00678730
Start Date
August 23 2007
End Date
September 11 2014
Last Update
March 9 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
VA Connecticut Healthcare System
West Haven, Connecticut, United States, 06516